1698024-73-5

Basic information

• Product Name: ARS-1323
• Synonyms: ARS-1323
• CAS NO: 1698024-73-5
• Molecular Formula: C21H17ClF2N4O2
• Molecular Weight: 430.8350864
• EINECS: -0
• Mol File: 1698024-73-5.mol

Chemical Properties

• Boiling Point: 614.7±55.0 °C(Predicted)
• Appearance: /
• Density: 1.434±0.06 g/cm3(Predicted)
• PKA: 6.03±0.35(Predicted)
• CAS DataBase Reference: ARS-1323(CAS DataBase Reference)
• NIST Chemistry Reference: ARS-1323(1698024-73-5)
• EPA Substance Registry System: ARS-1323(1698024-73-5)

Safety Data

• Hazardous Substances Data: 1698024-73-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ARS-1323 is used as an anti-inflammatory and immunosuppressive agent for its ability to inhibit the expression of pro-inflammatory cytokines and reduce the activation of immune cells. This makes it a potential treatment for various inflammatory and autoimmune diseases.
Used in Treatment of Inflammatory Conditions:
ARS-1323 is used as a therapeutic agent for inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease, where it has shown promising results in attenuating tissue damage and improving disease outcomes.
Used in Research and Development:
ARS-1323 is utilized in research for the development of novel anti-inflammatory drugs due to its unique mechanism of action and potential therapeutic benefits, making it an exciting area of study within the pharmaceutical and medical fields.

Upstream product

• 814-68-6 acryloyl chloride 
• 1698027-19-8 7-bromo-4,6-dichloro-8-fluoroquinazoline 
• 1698027-17-6 2-amino-4-bromo-5-chloro-3-fluorobenzoic acid 
• 1416013-62-1 2-amino-4-bromo-3-fluorobenzoic acid 
• 1336963-95-1 6-bromo-7-fluoroindoline-2,3-dione 
• 1336963-99-5 N-(3-bromo-2-fluorophenyl)-2-(hydroxyimino)acetamide 
• 58534-94-4 2-fluoro-3-bromonitrobenzene 

Relevant articles and documents

RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS

Provided herein are RAS protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a RAS-mediated disorder, disease, or condition.

METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES

Methods for preparing compounds having the following structure (I): (Formula (I)) or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b and R4c, are as defined herein are provided. Related compounds and methods for making the same are also provided.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.